NCT02683421View on ClinicalTrials.gov

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tilmanocept

Trial Locations (2)

90036

Axis Clinical Trials, Los Angeles

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY